The latest INSPIRE Phase 3 trial data on LIQ861 as a treatment for pulmonary arterial hypertension (PAH) support…
Articles by Alice Melão, MSc
Increased production of a protein called Nestin by cells lining the blood vessels in the lungs may contribute to the…
Treatment with Opsumit (macitentan) can significantly improve the heart’s right ventricular function, reverse cardiac tissue remodeling, and reduce pulmonary vascular…
Regenerative cell therapy can induce significant improvements in key clinical features of pulmonary arterial hypertension (PAH) in animal models, a…
The first patient has been given the investigational therapy CXA-10 in an ongoing Phase 2 trial in patients with…
Invasive pulmonary artery denervation is safe and can improve the outcome of patients with combined pre- and post-capillary pulmonary…
Preclinical and early clinical data showing the safety and potential therapeutic activity of rodatristat ethyl support its progression into…
Pulmonary hypertension (PH) is associated with poorer neurodevelopmental outcome and impaired growth in the first two years of life for…
Long-term treatment with Adempas (riociguat) can reduce right heart size and improve the heart’s pumping function in patients with…
Throughout the past year, Pulmonary Hypertension News has brought you information about important discoveries, treatment developments, clinical trials, and other…
Older patients diagnosed with pulmonary hypertension (PH) present a specific clinical profile and have a worse prognosis, a study shows.
The U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to software being developed by Bayer and…